8 January 2025
Hemogenyx Pharmaceuticals
plc
("Hemogenyx Pharmaceuticals" or the "Company")
Placing to raise
£340,000
Hemogenyx Pharmaceuticals plc (LSE:
HEMO) is pleased to announce that it has raised £340,000 through
the issue of 100,000 new ordinary shares ("Placing Shares") at a
price of 340p per share (the "Placing"). One institutional investor
has subscribed for the Placing Shares and has also been granted
50,000 warrants exercisable at a price of 500p each for a period of
12 months from 1 March 2025.
The Placing uses the Company's
current headroom to issue ordinary shares for cash. The net
proceeds of the Placing will be dedicated to the clinical trial of
the Company's lead asset, HG-CT-1, targeting relapsed/refractory
(R/R) acute myeloid leukemia (AML) in adults. The first patient for
the trial is recruited and being tested for inclusion/exclusion
criteria to satisfy the clinical protocol. The funds raised will
also assist the Company into the next stage of the
trials.
An application is being made to the
Main Market of the London Stock Exchange, and admission of the
Placing Shares to trading is expected on or around 15 January 2025
("Admission"). The Placing Shares will rank pari passu with the Company's
existing Ordinary Shares.
Total Voting Rights
For the purpose of the Disclosure
Guidance and Transparency Rules, following Admission the enlarged
issued share capital of the Company will comprise 3,604,539
ordinary shares. The Company does not hold any shares in treasury.
The above figure may be used by shareholders as the denominator for
the calculations by which they will determine if they are required
to notify their interest in, or a change to their interest in, the
Company, under the Disclosure Guidance and Transparency
Rules.
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have
been inside information for the purposes of Article 7 of
Regulation No 596/2014 (as it forms part of UK domestic law by
virtue of the European Union (Withdrawal) Act 2018) until the
release of this announcement. The person responsible for arranging
for the release of this announcement on behalf of Hemogenyx
Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive
Officer & Co-Founder.
Enquiries:
|
Hemogenyx Pharmaceuticals plc
|
https://hemogenyx.com
|
|
Dr Vladislav Sandler, Chief
Executive Officer & Co-Founder
|
headquarters@hemogenyx.com
|
|
Peter Redmond, Director
|
peter.redmond@hemogenyx.com
|
|
|
|
|
SP
Angel Corporate Finance LLP
|
Tel: +44 (0)20 3470 0470
|
|
Matthew Johnson, Vadim Alexandre,
Adam Cowl
|
|
|
|
|
|
Peterhouse Capital Limited
|
Tel: +44 (0)20 7469 0930
|
|
Lucy Williams, Duncan Vasey, Charles
Goodfellow
|
|
About Hemogenyx
Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a
publicly traded company (LSE: HEMO) headquartered in London, with
its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and
Immugenyx LLC, located in New York City at its state-of-the-art
research facility.
The Company is a clinical stage
biopharmaceutical group developing new medicines and treatments to
treat blood and autoimmune disease and to bring the curative power
of bone marrow transplantation to a greater number of patients
suffering from otherwise incurable life-threatening diseases.
Hemogenyx Pharmaceuticals is developing several distinct and
complementary product candidates, as well as a platform technology
that it uses as an engine for novel product development.